Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2019 Jan 31

PMID 30698728

Citations 1

Authors

Kevin J Cheung

Nancy E Davidson

Affiliations

Soon will be listed here.

Citing Articles

Comparing Local and Systemic Control between Partial- and Whole-Breast Radiotherapy in Low-Risk Breast Cancer-A Meta-Analysis of Randomized Trials.

Haussmann J, Budach W, Strnad V, Corradini S, Krug D, Schmidt L Cancers (Basel). 2021; 13(12).

PMID: 34199281 PMC: 8231985. DOI: 10.3390/cancers13122967.

References

Aalders K, van Bommel A, van Dalen T, Sonke G, van Diest P, Boersma L . Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. Eur J Cancer. 2016; 63:118-26. DOI: 10.1016/j.ejca.2016.05.010. View

Peto R, Davies C, Godwin J, Gray R, Pan H, Clarke M . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2011; 379(9814):432-44. PMC: 3273723. DOI: 10.1016/S0140-6736(11)61625-5. View

Kramer I, Schaapveld M, Oldenburg H, Sonke G, McCool D, van Leeuwen F . The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype. J Natl Cancer Inst. 2019; 111(7):709-718. DOI: 10.1093/jnci/djz010. View

Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami H . Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007; 25(27):4210-6. DOI: 10.1200/JCO.2006.10.5056. View

Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D . Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018; 379(2):111-121. PMC: 6172658. DOI: 10.1056/NEJMoa1804710. View

Schaapveld M, Visser O, Louwman W, Willemse P, de Vries E, van der Graaf W . The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2007; 110(1):189-97. PMC: 2440941. DOI: 10.1007/s10549-007-9709-2. View

Blum J, Flynn P, Yothers G, Asmar L, Geyer Jr C, Jacobs S . Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017; 35(23):2647-2655. PMC: 5549453. DOI: 10.1200/JCO.2016.71.4147. View

Nguyen Q, Pervolarakis N, Blake K, Ma D, Davis R, James N . Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity. Nat Commun. 2018; 9(1):2028. PMC: 5966421. DOI: 10.1038/s41467-018-04334-1. View

Karaayvaz M, Cristea S, Gillespie S, Patel A, Mylvaganam R, Luo C . Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun. 2018; 9(1):3588. PMC: 6123496. DOI: 10.1038/s41467-018-06052-0. View

10.

Font-Gonzalez A, Liu L, Voogd A, Schmidt M, Roukema J, Coebergh J . Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands. Breast Cancer Res Treat. 2013; 139(3):811-9. DOI: 10.1007/s10549-013-2588-9. View

11.

Li C, Daling J, Porter P, Tang M, Malone K . Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res. 2009; 69(17):6865-70. PMC: 2745902. DOI: 10.1158/0008-5472.CAN-09-1355. View

12.

Bouchardy C, Benhamou S, Fioretta G, Verkooijen H, Chappuis P, Neyroud-Caspar I . Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat. 2010; 127(1):233-41. DOI: 10.1007/s10549-010-1137-z. View

13.

Schaapveld M, Visser O, Louwman M, de Vries E, Willemse P, Otter R . Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol. 2008; 26(8):1239-46. DOI: 10.1200/JCO.2007.11.9081. View

14.

Gierach G, Curtis R, Pfeiffer R, Mullooly M, Ntowe E, Hoover R . Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncol. 2016; 3(2):186-193. PMC: 5757540. DOI: 10.1001/jamaoncol.2016.3340. View

15.

Nichols H, Berrington de Gonzalez A, Lacey Jr J, Rosenberg P, Anderson W . Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011; 29(12):1564-9. PMC: 3082975. DOI: 10.1200/JCO.2010.32.7395. View

16.

Cardoso F, Vant Veer L, Bogaerts J, Slaets L, Viale G, Delaloge S . 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375(8):717-29. DOI: 10.1056/NEJMoa1602253. View

17.

Hershman D, Kushi L, Shao T, Buono D, Kershenbaum A, Tsai W . Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010; 28(27):4120-8. PMC: 2953970. DOI: 10.1200/JCO.2009.25.9655. View

18.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V . Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012; 381(9869):805-16. PMC: 3596060. DOI: 10.1016/S0140-6736(12)61963-1. View

19.

Langballe R, Mellemkjaer L, Malone K, Lynch C, John E, Knight J . Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study. Breast Cancer Res. 2016; 18(1):65. PMC: 4940926. DOI: 10.1186/s13058-016-0726-0. View

20.

Giraddi R, Chung C, Heinz R, Balcioglu O, Novotny M, Trejo C . Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland Development. Cell Rep. 2018; 24(6):1653-1666.e7. PMC: 6301014. DOI: 10.1016/j.celrep.2018.07.025. View